Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases

被引：2

作者：

Shuttleworth, Stephen J. ^{[1
]}

Bailey, Sarah G. ^{[2
]}

Townsend, Paul A. ^{[1
,2
]}

机构：

[1] Karus Therapeut Ltd, Southampton SO16 7NP, Hants, England

[2] Univ Southampton, Div Human Genet, Sch Med, Southampton SO16 6YD, Hants, England

来源：

CURRENT DRUG TARGETS | 2010年 / 11卷 / 11期

关键词：

Histone deacetylases; inhibitors; inflammation; immune disease; FK228; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NITRIC-OXIDE SYNTHASE; VERSUS-HOST-DISEASE; KAPPA-B ACTIVATION; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; ULCERATIVE-COLITIS; BIOLOGICAL-ACTIVITIES; SYNOVIAL FIBROBLASTS; FUNGAL METABOLITE;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.

引用

页码：1449 / 1457

页数：9

共 80 条

[31] Suppression of caspase-11 expression by histone deacetylase inhibitors [J].

Heo, Hyejung ;

Yoo, Lang ;

Shin, Ki Soon ;

Kang, Shin Jung .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 378 (01) :79-83

[32] Expression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts [J].

Horiuchi, Marika ;

Morinobu, Akio ;

Chin, Takaaki ;

Sakai, Yoshitada ;

Kurosaka, Masahiro ;

Kumagai, Shunichi .

JOURNAL OF RHEUMATOLOGY, 2009, 36 (08) :1580-1589

[33] Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice [J].

Hu, N. ;

Long, H. ;

Zhao, M. ;

Yin, H. ;

Lu, Q. .

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2009, 38 (06) :464-471

[34] TWIN STUDIES IN RHEUMATIC DISEASES [J].

JARVINEN, P ;

AHO, K .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 1994, 24 (01) :19-28

[35] Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis [J].

Juengel, A. ;

Baresova, V. ;

Ospelt, C. ;

Simmen, B. R. ;

Michel, B. A. ;

Gay, R. E. ;

Gay, S. ;

Seemayer, C. A. ;

Neidhart, M. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) :910-912

[36]

JUNG HM, BIOMATERIALS, V1, P29

[37] THE PROMOTER OF THE HUMAN INTERLEUKIN-2 GENE CONTAINS 2 OCTAMER-BINDING SITES AND IS PARTIALLY ACTIVATED BY THE EXPRESSION OF OCT-2 [J].

KAMPS, MP ;

CORCORAN, L ;

LEBOWITZ, JH ;

BALTIMORE, D .

MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (10) :5464-5472

[38] Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model [J].

Kinugasa, Fumitaka ;

Yamada, Toshiko ;

Noto, Takahisa ;

Matsuoka, Hideaki ;

Mori, Hiroaki ;

Sudo, Yuji ;

Mutoh, Seitaro .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (09) :1723-1726

[39] Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model [J].

Kinugasa, Fumitaka ;

Nagatomi, Itsuo ;

Nakanishi, Tomonori ;

Noto, Takahisa ;

Mori, Hiroaki ;

Matsuoka, Hideaki ;

Sudo, Yuji ;

Mutoh, Seitaro .

TRANSPLANT IMMUNOLOGY, 2009, 21 (04) :198-202

[40]

Kleinert H, 1996, MOL PHARMACOL, V49, P15

← 1 2 3 4 5 6 7 8 →